2017
DOI: 10.1080/09273948.2017.1406529
|View full text |Cite
|
Sign up to set email alerts
|

The Collaborative Ocular Tuberculosis Study (COTS)-1 Report 3: Polymerase Chain Reaction in the Diagnosis and Management of Tubercular Uveitis: Global Trends

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
52
0
1

Year Published

2018
2018
2025
2025

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 64 publications
(55 citation statements)
references
References 18 publications
2
52
0
1
Order By: Relevance
“…50 The report also demonstrated that PCR analysis may not influence management or treatment outcomes in the real-world scenario. 50 Regarding cost-effectiveness, previous studies looking at the diagnosis of pulmonary TB have demonstrated significant cost saving benefits of PCR versus mycobacterial culture. 51 From our study, no extrapolations can be made about the cost-effectiveness of those techniques for ocular fluid analysis.…”
Section: Discussionmentioning
confidence: 94%
See 2 more Smart Citations
“…50 The report also demonstrated that PCR analysis may not influence management or treatment outcomes in the real-world scenario. 50 Regarding cost-effectiveness, previous studies looking at the diagnosis of pulmonary TB have demonstrated significant cost saving benefits of PCR versus mycobacterial culture. 51 From our study, no extrapolations can be made about the cost-effectiveness of those techniques for ocular fluid analysis.…”
Section: Discussionmentioning
confidence: 94%
“…The COTS-1 Report 3 studied the real-world evidence on the utility of PCR of ocular fluids in the management of ocular TB. 50 It showed that PCR analysis still needs significant advancement to gain wider acceptability worldwide. 50 The report also demonstrated that PCR analysis may not influence management or treatment outcomes in the real-world scenario.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…WHO currently recommends universal DST in its End TB Strategy [ 8 ]. Unfortunately, in 2016, only 26 of 48 surveyed countries reported a national policy and algorithms indicating universal access to DST, and globally, only 41% of bacteriologically confirmed new and previously treated cases were tested for at least rifampicin resistance [ 9 ]. Upon identifying resistance to rifampicin, recommended diagnostic algorithms assess susceptibility to additional drugs to determine whether the TB strain is multidrug resistant (i.e., MDR TB) or extensively drug resistant (i.e., XDR TB) [ 6 , 10 , 11 ].…”
Section: Patient Coveragementioning
confidence: 99%
“…Many countries conduct nationally representative drug resistance surveys for TB [ 6 ]. South Africa is one country that is transitioning away from TB drug resistance surveys after national scale-up of DST [ 9 , 18 ]. The continuous TB drug resistance surveillance system in Western Cape produced a rifampicin resistance estimate similar to that generated in a recent national survey (4.6% versus 4.3%, respectively) [ 19 ].…”
Section: Surveillance Approachesmentioning
confidence: 99%